When should Phesgo (pertuzumab + trastuzumab) be transitioned to trastuzumab alone?

When to Transition from Phesgo to Trastuzumab Alone

You should not routinely transition from Phesgo (pertuzumab + trastuzumab) to trastuzumab alone during active treatment, as dual HER2 blockade provides superior outcomes and should be maintained until disease progression or unacceptable toxicity. 1

Treatment Duration and Maintenance Strategy

During Active Chemotherapy Phase

When receiving Phesgo with chemotherapy, the standard approach is:

• Continue chemotherapy for 4-6 months (or longer) until maximal response, depending on toxicity and absence of progression 1, 2
• When chemotherapy is stopped, continue Phesgo (both pertuzumab and trastuzumab components) as maintenance therapy—no change in the HER2-targeted regimen is needed until progression or unacceptable toxicity 1, 2

This is a critical distinction: stopping chemotherapy does NOT mean stopping pertuzumab. Both HER2-targeted agents should continue together.

Early Breast Cancer Setting

For adjuvant or neoadjuvant treatment:

• Complete 1 year of dual HER2 blockade (up to 18 cycles of Phesgo every 3 weeks) 3
• Continue until disease recurrence or unmanageable toxicity, whichever occurs first 3
• The dual blockade has demonstrated superior outcomes, particularly in node-positive disease 4

Metastatic Breast Cancer Setting

• Continue Phesgo until disease progression or unmanageable toxicity 3
• The optimal duration in patients with long-term disease control is unknown, but continuation of dual HER2 blockade is recommended 5
• After several years of sustained complete remission, stopping anti-HER2 therapy may be considered in highly selected patients, particularly if treatment rechallenge is available upon progression 6, 7

When Trastuzumab Alone Might Be Appropriate

The only scenarios where trastuzumab monotherapy (without pertuzumab) is acceptable:

1. Disease progression on dual blockade: After progression on pertuzumab + trastuzumab, subsequent lines may use trastuzumab with different chemotherapy agents or switch to other HER2-targeted therapies like T-DM1 or trastuzumab deruxtecan 5

2. Pertuzumab contraindication or unavailability: If pertuzumab cannot be given due to specific contraindications or access issues 5

3. Unacceptable pertuzumab-specific toxicity: If pertuzumab must be discontinued due to toxicity, trastuzumab can continue alone 3

4. HR-positive disease with endocrine maintenance: In highly selected HR-positive/HER2-positive patients where endocrine therapy + anti-HER2 therapy was chosen (rather than chemotherapy), single-agent trastuzumab with endocrine therapy may be considered, though dual blockade is preferred 6

Key Evidence Supporting Dual Blockade Maintenance

The evidence strongly supports maintaining both agents:

• Studies demonstrate that pertuzumab monotherapy has minimal activity (3.4% response rate), while dual blockade with trastuzumab achieves 17.6% response rate even after trastuzumab progression 5
• Continuation of HER2 blockade after progression on trastuzumab-containing regimens provides benefit 5
• The CLEOPATRA trial established pertuzumab + trastuzumab + taxane as the preferred first-line regimen based on overall survival benefit 5

Common Pitfall to Avoid

Do not discontinue pertuzumab when stopping chemotherapy. This is a frequent misconception. The chemotherapy component can be stopped after 4-6 months or at maximal response, but both HER2-targeted agents (pertuzumab and trastuzumab in Phesgo) should continue as maintenance therapy until progression or toxicity 1, 2.